Amid the confusion of the pandemic, fundamental business strategies are reshaping the biosimilar playing field, according to corporate earnings reports.
Facing pending competition from Amgen’s eculizumab biosimilar in 2025, which challenges Alexion’s eculizumab (Soliris) product, Alexion said it has managed to convert 70% of Soliris patients to its ravulizumab follow-on (Ultomiris), which received FDA approval in 2018, also for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Soliris, an aging drug power hitter for Alexion, had net sales of $975.5 million in the second quarter, versus $980.8 million a year earlier. Ultomiris brought in $251.1 million in net sales for the quarter just ended, versus $54.2 million in the second quarter of 2019, a 363% increase, the company said.
“As anticipated, we have seen accelerated conversion from Soliris to Ultomiris,” the company said.
Alexion also noted that in the second quarter it received European Union approval for Ultomiris in atypical hemolytic uremic syndrome and announced positive phase 3 results for a weekly formulation of subcutaneous ravulizumab.
Alexion said it has phase 2/3 studies planned or underway for Soliris in neuromyelitis optica spectrum disorder and generalized myasthenia gravis. In addition, Japan’s ministry of health has granted Soliris an indication for Guillain-Barre syndrome.
Other Quarterly News
The second quarter of 2020 began and ended amid the coronavirus disease 2019 (COVID-19) pandemic, challenging biosimilar companies in new ways to achieve greater market share.
For Biogen, which partners on sales of biosimilars with Samsung Bioepis, during the 3 months ended June 30, 2020, sales of 3 biosimilar products—etanercept (Benepali), infliximab (Flixabi) and adalimumab (Imraldi)—dropped 7% to $171.6 million from $184.4 million in the same quarter a year ago.
Benepali’s sales totaled $106.2 million at end of the second quarter this year, down 12%; Imraldi’s, $44.8 million, down 5%; and Flixabi’s, $20.6 million. Sales of Flixabi rose 23%, from $16.8 million in the same quarter a year ago.
The company did not discuss reasons why the biosimilars performed worse than last year.
Frensenius Kabi
Frensenius, parent company of Fresenius Kabi, which has adalimumab, tocilizumab, and pegfilgrastim biosimilars in the pipeline, saw growth in sales of 2% but a decline in net income ($482 million) of 13% for the quarter just ended, compared with the same quarter in 2019.
For the first half of 2020, net income was down 6%, at $1.03 billion.
In May, Frensenius Kabi signed an agreement with Germany-based company medac, to market its adalimumab biosimilar Idacio in Germany. Medac provides methotrexate for the treatment of chronic inflammatory diseases and is often used in conjunction with adalimumab products.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
2 Commerce Drive
Cranbury, NJ 08512